Nuvation Bio to Present at the Jefferies London Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Jefferies London Healthcare Conference in London, U.K., on Tuesday, November 19, 2024, at 3:30 a.m. ET/8:30 a.m. GMT.

A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.

About Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112616629/en/

Nuvation Bio Investor Contact:
[email protected]

Nuvation Bio Media Contact:
[email protected]

Source: Nuvation Bio Inc.

You May Also Be Interested In

• Upland Software Reports Second Quarter 2026 Financial Results
• TransPerfect Honored as BPO of the Year Finalist at Customer Contact Week Excellence Awards
• NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Availability of Section 19(a) Notice for August 2026